RORγ

RORγ Related Products (42):

By Type:	Pan (3) Selective (24)
By Effects:	Inhibitors (20) Agonists (7) Antagonists (10) Activator (1) Modulators (3) Ligand (1)

Cat. No.	Product Name	Effect	Purity

HY-113238A

Lithocholic acid 3-sulfate disodium	Ligand	99.93%
Lithocholic acid 3-sulfate disodium is a GPR39 agonist, with EC₅₀ values of 41 μM and 42.4 μM in M39-20 and hGPR39-2 cells, respectively, in the absence of Zn²⁺, and 0.88 μM and 0.97 μM in the presence of Zn²⁺. Lithocholic acid 3-sulfate disodium acts as a RORγt ligand. Lithocholic acid 3-sulfate disodium stimulates the GPR39 receptor to initiate intracellular calcium signaling, independent of the Zn²⁺-binding sites H17 and H19. LCA-3-S selectively inhibits Th17 cell differentiation by targeting RORγt. Lithocholic acid 3-sulfate disodium can be used in the research of cholestatic liver diseases.

HY-143712

Allolithocholic acid	Inhibitor	99.69%
Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC₅₀ = 2.7 μM) and RORγt inverse agonist (IC₅₀ = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease.

HY-120210

XY018	Antagonist	99.68%
XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC₅₀, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD).

HY-113345

Zymostenol	Agonist	99.33%
Zymostenol (5a-Cholest-8-en-3b-ol) is a late-stage precursor in the biosynthesis of cholesterol. Zymostenol is a RORγ agonist (EC₅₀: 1 μM).

HY-19775

GNE-6468	Antagonist	98.02%
GNE-6468 is a highly potent and selective RORγ (RORc) inverse agonist with an EC₅₀ value of 13 nM for HEK-293 cell. GNE-6468 exhibits an EC₅₀ of 30 nM for IL-17 PBMC.

HY-180813

RORγ-IN-3	Inhibitor
RORγ-IN-3 (Compound 21) is a potent and highly selective RORγ inhibitor with an EC₅₀ of 84 nM. RORγ-IN-3 can effectively inhibit the production of IL-17, with an IC₅₀ value of 1.0 μM. RORγ-IN-3 can be used for the study of autoimmune diseases.

HY-183763

RORγt inverse agonist 37	Agonist
RORγt inverse agonist 37 is an orally active RORγt inverse agonist with an IC₅₀ of 10.8 nM against human targets. RORγt inverse agonist 37 destabilizes helix 12 of RORγt in the agonist-bound conformation, thereby inhibiting transcriptional activity. RORγt inverse agonist 37 inhibits the secretion of IL-17 in cells and in LPS-induced systemic inflammation mouse models. RORγt inverse agonist 37 improves disease-related symptoms in mouse models of psoriasiform dermatitis. RORγt inverse agonist 37 can be used in research related to psoriasiform dermatitis and systemic inflammation.

HY-182716

BMS-336	Inhibitor
BMS-336 (Compound 89) is a RORγ inhibitor. BMS-336 can be used for the research of cancer.

HY-163436

F44-A13	Antagonist
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC₅₀ value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders.

HY-152851

Izumerogant	Inhibitor	99.95%
Izumerogant (IMU-935) is an orally active RORγ/DHODH dual inhibitor with IC₅₀s of 10 and 98 nM against RORγ and DHODH. Izumerogant efficiently blocks the replication of SARS-CoV-2, HCMV and HAdV5 with EC₅₀ values between 3.6 and 17 nM. Izumerogant can be used for researching antiviral properties.

HY-139780

JNJ-61803534	Inhibitor	99.84%
JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC₅₀ of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions.

HY-126037

(±)-ML 209	Antagonist	98.14%
(±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor RORγ antagonist with an IC₅₀ of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC₅₀ of 300 nM in HEK293t cells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4⁺ T cells into other lineages, including Th1 and regulatory T cells.

HY-138115

7ß,27-Dihydroxycholesterol	Activator	99.58%
7ß,27-Dihydroxycholesterol (7β, 27-OHC) is a potent and selective activator of RORγt (K_i=120 nM). 7ß,27-Dihydroxycholesterol promotes the differentiation of mouse and human CD4⁺ Th17 cells. 7ß,27-Dihydroxycholesterol also increases the production of IL-17 depended on CYP27A1.

HY-131338

RORγt inverse agonist 13	Inhibitor	98.13%
RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved agent-like properties, with an IC₅₀ of 63.8 nM.

HY-120785

SR1555	Antagonist	99.69%
SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC₅₀ value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases.

HY-16983

GNE-3500	Antagonist	98.90%
GNE-3500 is a selective, orally active antagonist for Retinoic Acid Receptor-Related Orphan Receptor C (RORc, also known as RORγ or NR1F3) with an EC₅₀ of 12 nM. GNE-3500 exhibits good pharmacokinetic characteristics in rats.

HY-103637A

Vimirogant hydrochloride	Inhibitor	98.39%
Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (K_i=3.5 nM; IC₅₀=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research.

HY-133552

RORγt Inverse agonist 10	Antagonist	99.13%
RORγt Inverse agonist 10 is a potent and orally bioavailable RORγt (retinoic acid receptor-related orphan nuclear receptor gamma t) inverse agonist, with an IC₅₀ of 51 nM. RORγt is a major transcription factor of genes related to psoriasis pathogenesis such as IL-17A, IL-22, and IL-23R

HY-119366

S18-000003	Inhibitor	99.31%
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC₅₀ of <30 nM towards human RORγt in competitive binding assays. S18-000003 shows selectivity for RORγt over other ROR family members (IC₅₀>10 μM). S18-000003 can be used for the research of psoriasis with low risk of thymic aberrations.

HY-W150866

Hexyl 4-hydroxybenzoate	Agonist	99.83%
Hexyl 4-hydroxybenzoate (Hexylparaben) is a retinoic acid-related orphan receptor RORγ(t) agonist with an EC₅₀ of 144 nM. Hexyl 4-hydroxybenzoate is used in the study of autoimmune diseases.

Name
Email *

	Sorry, but the email address you supplied was invalid.